ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: We previously reported that GZD824, synthesized by hybridizing the structural moieties from the FDA-approved drugs IM, nilotinib, and dasatinib, is capable of inhibiting BCR/ABL kinase and eliminating Ph+ CML cells [13].